<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944043</url>
  </required_header>
  <id_info>
    <org_study_id>TQ05105-Ⅰb/Ⅱ-02</org_study_id>
    <nct_id>NCT04944043</nct_id>
  </id_info>
  <brief_title>A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease</brief_title>
  <official_title>A Single Group, Open-Label, Multicenter ,Phase Ⅰb/Ⅱ Clinical Trials of TQ05105 Tablet in Patients With Glucocorticoid Refractory and Dependent Moderate to Severe Chronic Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a single arm, open label, multicenter phase Ib / II trial in subjects with&#xD;
      glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two&#xD;
      phases: phase I for the dose exploration and phase II for the extension study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug tolerance of the first cycle</measure>
    <time_frame>Baseline up to 4 weeks</time_frame>
    <description>Dose-limiting toxicity events related to the investigational drug occured within 28 days after initial administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate (ORR)</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) during the study according to the cGVHD NIH Consensus Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>OS defined as the time from first dose to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality（NRM）</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>Defined as the date of first dose to the date of death from non hematologic disease recurrence / progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure Free Survival (FFS)</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Defined as absence of relapse, death, or need for additional systemic immunosuppressant cGVHD therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucocorticoid dose</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>The reduction in glucocorticoid requirement would be regarded as an effect of the trial drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in symptom burden</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>Evaluate changes in symptom burden as measured by the Lee Symptom Scale. A change of 7 points on the Lee Symptom Scale will be considered clinically significant and relates to improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 1; Pre-dose of day 3,day5, day 6 ;Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 7.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQ05105 or metabolite(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 1; Pre-dose of day 3,day5, day 6 ;Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 7.</time_frame>
    <description>To characterize the pharmacokinetics of TQ05105 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 1; Pre-dose of day 3,day5, day 6 ;Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 7.</time_frame>
    <description>To characterize the pharmacokinetics of TQ05105 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Chronic Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>TQ05105 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ05105 tablet 10mg given orally, twice daily in 28-cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ05105 Tablet</intervention_name>
    <description>TQ05105 tablet is a JAK inhibitor, which can inhibit the abnormal activation of JAK2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.</description>
    <arm_group_label>TQ05105 Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Understood and signed an informed consent form. 2. ≥12 years old, Karnofsky&#xD;
             Performance Scale of ≥60, life expectancy ≥ 6 months.&#xD;
&#xD;
             3. Has received allogeneic hematopoietic stem cell transplantation (alloSCT). 4.&#xD;
             Clinically diagnosed moderate to severe cGVHD according to NIH Consensus Criteria.&#xD;
&#xD;
             5. Has received systemic or topical corticosteroids therapy and confirmed&#xD;
             steroid-refractory/dependent cGVHD according to NIH Consensus Criteria.&#xD;
&#xD;
             6. Has received at least 1 lines of therapy for cGVHD. 7. Adequate laboratory&#xD;
             indicators. 8. No pregnant or breastfeeding women, and a negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Has active acute GVHD. 2. Has previously failed to respond to JAK inhibitors for&#xD;
             GVHD, or who had used JAK inhibitors within 4 weeks before the first administration.&#xD;
&#xD;
             3. Has uncontrollable active infections or infections requiring systematic treatment&#xD;
             within 7 days before the first administration.&#xD;
&#xD;
             4. Development of other basic diseases. 5. Has malignant tumors within 3 years. 6. Has&#xD;
             multiple factors affecting oral medication. 7. Has substance abuse or a psychotic&#xD;
             disorder. 8. Has severe and / or uncontrolled disease. 9. Allergic to drugs or its&#xD;
             constituents. 10. Has participated in any other clinical trials within 4 weeks before&#xD;
             first administration.&#xD;
&#xD;
             11. According to the judgement of the investigators, there are other factors that may&#xD;
             lead to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>He Huang, Doctor</last_name>
    <phone>0571-87236703</phone>
    <email>hehuangyu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, Doctor</last_name>
      <phone>0571-87236703</phone>
      <email>hehuangyu@126.com</email>
    </contact>
    <investigator>
      <last_name>He Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

